Ocular Therapeutix Reports Second Quarter 2025 Financial Results

Published on August 6, 2025
BEDFORD, Mass.—Biopharmaceutical company Ocular Therapeutix Inc., (NASDAQ: OCUL) a leader in the retina space, has announced financial results for the second quarter ended June 30, 2025, and provided recent business highlights. The company reported raising gross proceeds of approximately $97 million in June through an existing ATM facility, and as of June 30, 2025, reported a cash balance of $391.1 million, with expected runway into 2028. Total net revenue was reported at $13.5 million for the second quarter of 2025, an 18.1 percent decrease compared with total net revenue of $16.4 million in the comparable quarter in 2024. The company also reported a net loss of $67.8 million for the second quarter of 2025, compared with a net loss of $43.8 million for the comparable quarter of 2024.
Continue reading on website
Other news

Topcon acquires Intelligent Retinal Imaging Systems, bolstering AI-powered screenings

August 5, 2025
Integrating IRIS technologies will allow Topcon to improve retinal disease diagnostics and referrals from primary care providers.

Myopic macular degeneration market analysis estimates significant growth in the next decade

August 6, 2025
Diagnostic tools, therapeutic innovations such as anti- anti-vascular endothelial growth factor (VEGF) therapies, and supportive technologies to manage vision loss form the myopic macular degeneration market.